Investor Presentaiton

Sartorius Group Bioprocess Solutions: Recurring business continues to recover while equipment remains soft Order intake € in millions Sales revenue Underlying EBITDA & margin € in millions € in millions 15.0% cc -5.3% cc 13.4% -6.9% -11.1% 695 653 576 647 217 193 SARTORIUS Q1 2023 Q1 2024 ■ M&A contributes ~3pp to sales development ◉ Q1 2023 Q1 2024 31,2 29,8 Q1 2023 Q1 2024 Ol growth in all regions, however China down; continuous recovery of recurring business also vs. relatively positive Q4 2023; muted investment activity dampens equipment business ■ UI. EBITDA margin on robust level; lower volumes partly compensated by positive product mix effects and cost base adjustments 40 40

View entire presentation